Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1840-1842

  Belanger, Paul ^a   Nast, Cynthia C ^b   Fratti, Rutilio ^a   Sanati, Homayoon ^a   Ghannoum, Mahmoud ^c,d  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDA; CELL WALL; DEGRADATION; DRUG EFFECT; FUNGUS GROWTH; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; MORPHOLOGY; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

EID: 0030877418     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1840     Document Type: Article

References (9)

1. Denning, D., A. del Favero, E. Gluckman, D. Norfolk, M. Ruhnke, S. Yonren, P. Troke, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Ghannoum, M. A. 1986. Effects of antincoplastic agents on growth, morphology, and metabolism of Torulopsis glabrata. Mycopathologia 95:175-181.
3. Ghannoum, M. A., K. Abu Elteen, M. Ellabib, and P. A. Whittaker. 1990. Antimycotic effects of octenidine and pirtenidine. J. Antimicrob. Chemother. 25:237-245.
4. Hitchcock, C. A., G. W. Pye, G. P. Oliver, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro, abstr. F72. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Hitchcock, C. A., and P. J. Whittle. 1993. Chemistry and mode of action of fluconazole, p. 183-197. In J. W. Rippon and R. A. Fromtling (ed.), Cutaneous antifungal agents: selected compounds in clinical practice and development. Marcel Dekker, Inc., New York, N.Y.
6. Jezequel, S. G., M. Clark, S. Cole, K. E. Evans, and P. Wastall. 1995 UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pre-clinical pharmacokinetics, abstr. F76. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeast; tentative standard, M27-T. National Committee for Clinical Laboratory Standards, Wayne, Pa.
8. Pesti, M., J. M. Campbell, and J. F. Peberdy. 1981. Alterations of ergosterol content and chitin synthase activity in Candida albicans. Curr. Microbiol. 5:187-190.
9. Sanati, H., P. H. Belanger, R. A. Fratti, and M. A. Ghannoum. 1996. Effect of voriconazole (UK-109,496) on the sterol biosynthesis of Candida albicans and Candida krutsei, abstr. C65. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.